(ASLeap) Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

Purpose

Escalating the dose of Cosentyx is currently one approach for treating certain rheumatologic conditions. The purpose of this study is to discover if it is beneficial to double the standard dose of the biologic drug Cosentyx for patients with Ankylosing Spondylitis (AS). Patients with an AS diagnosis who have not responded to one biologic drug therapy or who have never been on a biologic, for whom other treatments (such as with NSAIDs) are not effective are invited to contact the study team to see if they could benefit from participating in this study.

Eligibility

  • Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent
  • Male or non-pregnant, non-lactating female patients at least 18 years of age
  • Diagnosis of moderate to severe Ankylosing Spondylitis (AS) with prior documented radiologic evidence fulfilling the Modified New York criteria for AS
  • Active AS assessed by total Bath Ankylosing Spondylitis Disease Activity index (BASDAI) ≥ 4 (0-10) at baseline
  • Total back pain as measured by visual analog scale (VAS) ≥ 40 mm (0-100 mm) at baseline
  • Spinal pain as measured by BASDAI question #2 ≥ 4 cm (0-10 cm) at baseline
  • Patients should have been on non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum tolerated dose for at least 4 weeks prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if withdrawn for intolerance, toxicity or contraindications
  • Stable dose of NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for at least 2 weeks before their Baseline Visit
  • Patients who have been on a tumor necrosis factor alpha (TNFα) inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFα agent

Additional inclusion and exclusion criteria apply. 

Age

18 to 65
65 and over

Gender

Male
Female

Keywords

Ankylosing Spondylitis

Principal Investigator

Michael R Bubb, M.D.

Department

Rheumatology

Contact Information

novartis.email@novartis.com

1-888-669-6682


Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at UFStudies@health.ufl.edu.

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams